Drugmaker Shire to buy Baxalta for $32bnDrugmaker Shire clinched its six-month pursuit of Baxalta International on Monday with an agreed $32 billion cash and stock offer, catapulting it to a leading position in treating rare diseases. The London-listed group, which firs More… |
Drugmaker Shire to buy Baxalta for $32bnDrugmaker Shire clinched its six-month pursuit of Baxalta International on Monday with an agreed $32 billion cash and stock offer, catapulting it to a leading position in treating rare diseases. The London-listed group, which firs More… |
Takeda acquires biologics manufacturing facility in USTakeda Pharmaceutical Company, a research-based global company, has acquired a biologics manufacturing facility located in Brooklyn Park, Minnesota (US), from Baxalta US. The firm intends to use the facility pr More… |
Takeda acquires biologics manufacturing facility in USTakeda Pharmaceutical Company, a research-based global company, has acquired a biologics manufacturing facility located in Brooklyn Park, Minnesota (US), from Baxalta US. The firm intends to use the facility pr More… |